文献速递临床试验与 GCP

沙库巴曲缬沙坦对比依那普利对射血分数降低心力衰竭患者主动脉僵硬度的影响:一项随机临床试验

Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

这项随机双盲试验在85个美国中心纳入464例射血分数≤40%的心力衰竭患者,比较沙库巴曲缬沙坦(n=231,目标剂量97/103 mg每日两次)与依那普利(n=233,目标剂量10 mg每日两次)治疗12周对中心主动脉僵硬度的影响。主要终点主动脉特征阻抗(Zc)变化组间无显著差异(治疗差-2.2 dyne×s/cm5,95%CI -17.6至13.2,P=0.78)。沙库巴曲缬沙坦在左房容积、左室舒张末期容积指数、左室收缩末期容积指数和二尖瓣E/e'比值上较依那普利有更大降低。

要点

  • 沙库巴曲缬沙坦对比依那普利未显著降低中心主动脉僵硬度(Zc治疗差-2.2 dyne×s/cm5,P=0.78)。
  • 沙库巴曲缬沙坦较依那普利更降低左房容积、LVEDVI、LVESVI和二尖瓣E/e'比值。
  • 两组不良事件包括低血压发生率相似(1.7% vs 3.9%)。

核心结论

  • 与依那普利相比,沙库巴曲缬沙坦治疗射血分数降低心力衰竭未显著降低中心主动脉僵硬度。
  • 研究结果可能有助于理解沙库巴曲缬沙坦在射血分数降低心力衰竭中作用的机制。

研究设计与样本

  • 随机双盲临床试验,2016年8月17日至2018年6月28日在美国85个中心纳入464例射血分数≤40%的心力衰竭患者,随访于2019年1月26日完成。
  • 参与者按1:1随机接受沙库巴曲缬沙坦(n=231;目标剂量97/103 mg每日两次)或依那普利(n=233;目标剂量10 mg每日两次)治疗12周。
  • 464例有效随机参与者平均年龄67.3岁(SD 9.1),女性占23.5%,427例完成研究。

主要发现

  • 12周时Zc在沙库巴曲缬沙坦组从223.8降至218.9 dyne×s/cm5,在依那普利组从213.2升至214.4 dyne×s/cm5(治疗差-2.2,95%CI -17.6至13.2,P=0.78)。
  • 9个预设次要终点中4个基线变化组间无显著差异,包括左室射血分数(沙库巴曲缬沙坦组34%至36% vs 依那普利组33%至35%;治疗差0.6%,95%CI -0.4%至1.7%,P=0.24)。
  • 沙库巴曲缬沙坦较依那普利更降低左房容积(30.4降至28.2 mL/m2 vs 29.8升至30.5 mL/m2;治疗差-2.8 mL/m2,95%CI -4.0至-1.6,P<0.001)。
  • 沙库巴曲缬沙坦较依那普利更降低LVEDVI(75.1降至70.3 mL/m2 vs 79.1降至75.6 mL/m2;治疗差-2.0 mL/m2,95%CI -3.7至0.3,P=0.02)。
  • 沙库巴曲缬沙坦较依那普利更降低LVESVI(50.8降至46.3 mL/m2 vs 54.1降至50.6 mL/m2;治疗差-1.6 mL/m2,95%CI -3.1至-0.03,P=0.045)和二尖瓣E/e'比值(13.8降至12.3 vs 13.4升至13.8;治疗差-1.8,95%CI -2.8至-0.8,P=0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Compared with enalapril, sacubitril-valsartan reduces cardiovascular mortality and heart failure hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). These benefits may be related to effects on hemodynamics and cardiac remodeling. OBJECTIVE: To determine whether treatment of HFrEF with sacubitril-valsartan improves central aortic stiffness and cardiac remodeling compared with enalapril. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind clinical trial of 464 participants with heart failure and ejection fraction of 40% or less enrolled across 85 US sites between August 17, 2016, and June 28, 2018. Follow-up was completed on January 26, 2019. INTERVENTIONS: Randomization (1:1) to sacubitril-valsartan (n = 231; target dosage, 97/103 mg twice daily) vs enalapril (n = 233; target dosage, 10 mg twice daily) for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was change from baseline to week 12 in aortic characteristic impedance (Zc), a measure of central aortic stiffness. Prespecified secondary outcomes included change from baseline to week 12 in N-terminal pro-B-type natriuretic peptide, ejection fraction, global longitudinal strain, mitral annular relaxation velocity, mitral E/e' ratio, left ventricular end-systolic and end-diastolic volume indexes (LVESVI and LVEDVI), left atrial volume index, and ventricular-vascular coupling ratio. RESULTS: Of 464 validly randomized participants (mean age, 67.3 [SD, 9.1] years; 23.5% women), 427 completed the study. At 12 weeks, Zc decreased from 223.8 to 218.9 dyne × s/cm5 in the sacubitril-valsartan group and increased from 213.2 to 214.4 dyne × s/cm5 in the enalapril group (treatment difference, -2.2 [95% CI, -17.6 to 13.2] dyne × s/cm5; P = .78). Of 9 prespecified secondary end points, no significant between-group difference in change from baseline was seen in 4, including left ventricular ejection fraction (34%-36% with sacubitril-valsartan vs 33 to 35% with enalapril; treatment difference, 0.6% [95% CI, -0.4% to 1.7%]; P = .24). However, greater reductions from baseline were seen with sacubitril-valsartan than with enalapril in all others, including left atrial volume (from 30.4 mL/m2 to 28.2 mL/m2 vs from 29.8 mL/m2 to 30.5 mL/m2; treatment difference, -2.8 mL/m2 [95% CI, -4.0 to -1.6 mL/m2]; P < .001), LVEDVI (from 75.1 mL/m2 to 70.3 mL/m2 vs from 79.1 mL/m2 to 75.6 mL/m2; treatment difference, -2.0 mL/m2 [95% CI, -3.7 to 0.3 mL/m2]; P = .02), LVESVI (from 50.8 mL/m2 to 46.3 mL/m2 vs from 54.1 to 50.6 mL/m2; treatment difference, -1.6 mL/m2 [95% CI, -3.1 to -0.03 mL/m2]; P = .045), and mitral E/e' ratio (from 13.8 to 12.3 vs from 13.4 to 13.8; treatment difference, -1.8 [95% CI, -2.8 to -0.8]; P = .001). Rates of adverse events including hypotension (1.7% vs 3.9%) were similar in both groups. CONCLUSIONS AND RELEVANCE: Treatment of HFrEF with sacubitril-valsartan, compared with enalapril, did not significantly reduce central aortic stiffness. The study findings may provide insight into mechanisms underlying the effects of sacubitril-valsartan in HFrEF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02874794.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Desai AS, Solomon SD, Shah AM, et al. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2019. PMID: 31475296. doi:10.1001/jama.2019.12843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。